Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - leukemia
17
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 COMPASS mutant cancer
NU 2022-053 INVENTORS Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* SHORT DESCRIPTION A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 4/29/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s):
Bladder cancer
,
Breast cancer
,
Cancer/Oncology
,
Colon cancer
,
Gastric cancer
,
Leukemia
,
Lung cancer
,
Lymphoma
,
Prostate cancer
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms
SHORT DESCRIPTION Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs). NU Tech IDs: NU 2018-169, NU 2021-005 PRINCIPAL INVESTIGATOR Peng Ji Northwestern University Feinberg School of Medicine, Department of Pathology IP...
Published: 4/16/2026
|
Updated: 4/16/2026
|
Inventor(s):
Keywords(s):
Breast cancer
,
Cancer/Oncology
,
Colon cancer
,
Leukemia
,
Lung cancer
,
Pancreatic cancer
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081 INVENTORS Sarki Abdulkadir (PI)* Northwestern University Feinberg School of Medicine, Department of Urology Gary Schiltz (PI)* Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of
leukemia
and prostate...
Published: 4/7/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Cancer/Oncology
,
Leukemia
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
New Therapeutic Approach for the Treatment of Acute Myeloid
Leukemia
NU 2017-214 Inventors Ali Shilatifard* Zibo Zhao Short Description A new therapeutic approach for the treatment of acute myeloid
leukemia
using casein kinase inhibitors. Background Leukemia is a group of cancers that affects the bone marrow and results in the overproduction of dysfunctional white blood cells (WBCs). The mixed lineage leukemia...
Published: 3/31/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Leukemia
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Small Molecules that Inhibit RNA Binding Protein IGF2BP3 in Cancer (UCLA Case No. 2023-215)
UCLA researchers in the Department of Pathology and Laboratory Medicine have developed small molecules which inhibits the protein IGF2BP3, a highly expressed oncofetal protein in certain cancers, especially in B-acute lymphoblastic
leukemia
. BACKGROUND: Cancer remains the second leading cause of death in the U.S. Advancements in targeted therapies...
Published: 1/7/2026
|
Updated: 11/5/2024
|
Inventor(s):
Dinesh Rao
Keywords(s):
blood cancers
,
Cancer
,
cancer inhibition
,
leukemia
Category(s):
Therapeutics > Oncology
Identification of a Factor That Rescues Dysregulated Endocytosis in Cultured Human Hematopoietic Stem Cells (UCLA Case No. 2023-051)
UCLA researchers in the Departments of Molecular, Cell & Developmental Biology have developed a novel method to enhance the function of hematopoietic stem cells (HSCs) to improve the transplantability of ex vivo expanded human HSCs in clinical settings. BACKGROUND: Hematopoietic stem cells (HSCs), present in blood and bone marrow, can form mature...
Published: 12/2/2025
|
Updated: 10/3/2024
|
Inventor(s):
Hanna Mikkola
,
Julia Aguade Gorgorio
Keywords(s):
bone marrow
,
bone marrow transplants
,
CRISPR
,
endocytosis
,
engraftment
,
environmental sensing
,
hematopoietic stem cells
,
leukemia
,
MLLT3
,
MYCT1
,
transplantability
Category(s):
Therapeutics > Hematology
,
Life Science Research Tools
,
Therapeutics > Stem Cells And Regenerative Medicine
Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Description of Technology: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than...
Published: 4/23/2026
|
Updated: 8/2/2023
|
Inventor(s):
James Kochenderfer
,
Norris Lam
Keywords(s):
act
,
adoptive cell therapy
,
Autoimmune
,
B Cell Malignancies
,
BICISTRONIC
,
CAR
,
CD19
,
CD20
,
chimeric antigen receptor
,
Kochenderfer
,
Leukemia
,
lymphoma
,
Monospecific
Category(s):
Application > Therapeutics
,
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Immunology
,
TherapeuticArea > Oncology
Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20
Abstract: CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and
leukemia
s, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression...
Published: 5/14/2025
|
Updated: 8/2/2023
|
Inventor(s):
James Kochenderfer
,
Shicheng Yang
Keywords(s):
act
,
adoptive cell therapy
,
B Cell Malignancies
,
BICISTRONIC
,
CAR
,
CD19
,
CD20
,
chimeric antigen receptor
,
Kochenderfer
,
Leukemia
,
lymphoma
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
TherapeuticArea > Oncology
,
Application > Therapeutics
B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic
Leukemia
Abstract: B-cell chronic lymphocytic
leukemia
(B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes. Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST). However, there is less than a 50% chance of finding a matching...
Published: 4/22/2025
|
Updated: 8/2/2023
|
Inventor(s):
Christoph Rader
,
Sivasubramanian Baskar
,
Jessica Suschak
,
Ivan Samija
,
Michael Bishop
Keywords(s):
alloHSCST
,
B-CELL
,
Leukemia
,
Lymphocytic
Category(s):
Application > Therapeutics
,
TherapeuticArea > Oncology
,
Collaboration Sought > Licensing
Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine
Leukemia
Virus gp70
Hybridoma cell line 715 expresses monoclonal antibody specific for Moloney murine
leukemia
virus (MuLV) gp70. Details may be found under NIH AIDS Reagent Program Catalog Number 1278: https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1278.aspx .
Published: 8/13/2025
|
Updated: 12/6/2022
|
Inventor(s):
Bruce Chesebro
Keywords(s):
715
,
Cell
,
DDXXXX
,
Detect
,
Hybridoma
,
Leukemia
,
Line
,
Listed LPM Ano as of 4/15/2015
,
Mab
,
moloney
,
Murine
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
RM
,
virus
,
VLXXXX
,
WIXXXX
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
1
2